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Background: Identifying hepatitis C virus (HCV) geno-
types has become increasingly important for determin-
ing clinical course and the outcome of antiviral therapy.
Here we describe the development of restriction frag-
ment mass polymorphism (RFMP) analysis, a novel
matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) assay suit-
able for high-throughput, sensitive, specific genotyping
of multiple HCV species.
Methods: The assay is based on PCR amplification and
mass measurement of oligonucleotides containing gen-
otype-specific motifs in the 5 untranslated region, into
which a type IIS restriction endonuclease recognition
was introduced by PCR amplification. Enzymatic cleav-
age of the products led to excision of multiple oligonu-
cleotide fragments representing variable regions whose
masses were determined by MALDI-TOF MS.
Results: The RFMP assay identified viral genotypes
present at concentrations as low as 0.5% and reliably
determined their relative abundance. When sera from
318 patients were analyzed, the RFMP assay exhibited
100% concordance with results obtained by clonal se-
quencing and identified mixed-genotype infections in
22% of the samples, in addition to several subtype
variants.
Conclusions: The RFMP assay has practical advantages
over existing methods, including better quantitative
detection of mixed populations and detection of geno-
type variants without need for population-based clon-
ing, enabling reliable viral genotyping in laboratories
and efficient study of the relationship between viral
genotypes and clinical outcome.
© 2005 American Association for Clinical Chemistry
Hepatitis C virus (HCV)3 demonstrates a high degree of
sequence variation, which provides the basis for grouping
the virus into 6 major genotypes and multiple subtypes
(1, 2). These groupings have served as important tools for
studying the geographic distribution of HCV genotypes,
their routes of transmission, and their association with
particular risk groups. Associations between viral geno-
type, interferon responsiveness, progression of disease,
and the likelihood of developing hepatocellular carci-
noma have been demonstrated (3–8). The HCV genotype
has emerged as an important factor in predicting the
response to and determining the duration of antiviral
therapy, such as interferon in combination with ribavirin,
with genotype 1 infections having less favorable response
rates and requiring longer treatment (9, 10). HCV geno-
typing thus is firmly established as part of the pretreat-
ment evaluation of patients with chronic infections, as
proposed by the European Association of Study of Liver
consensus conference in 1999 (11 ) and the NIH consensus
conference in 2002 (12 ).
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Many HCV genotyping methods have been developed,
including restriction fragment length polymorphism anal-
ysis, genotype-specific PCR, heteroduplex mobility anal-
ysis, melting curve analysis with fluorescence resonance
energy transfer probes, and line probe assay, a DNA
hybridization method; however, nucleotide sequencing of
an appropriate subgenomic region remains the most
widely accepted method (13–18). Most of these methods,
however, are labor-intensive, complex to standardize,
and/or ineffective for determining multiple HCV geno-
types in an experimental setup. Because of a high rate of
mutation, extensive HCV genetic heterogeneity may oc-
cur in an individual during the course of infection, and
more than 1 genotype may occur in some patients, par-
ticularly in individuals who have received multiple trans-
fusions or are intravenous drug users (19 ). The perceived
rate of quasispecies and mixed-genotype infections is
highly variable in patients tested by different assays (20 ),
and it is difficult to assess the true prevalence of mixed
infection by current methods because they are designed to
identify only the predominant HCV genotype in the
population. The presence or clinical significance of mixed-
genotype infection thus may be underestimated (19, 21).
We have recently developed a matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS)–based genotyping assay that exploits
differences between wild-type and variant sequences in
hepatitis B virus (22 ). In the current study, we used
restriction fragment mass polymorphism (RFMP) analy-
sis, an advanced MALDI-TOF MS–based assay, for HCV
genotyping capable of differentiating a cluster of multiple
variations in the 5 untranslated region (UTR). We as-
sessed the sensitivity and reliability of the assay by
comparing the results with direct or clonal sequencing;
we then used the RFMP assay to determine the genotype
distribution and prevalence of mixed-genotype infections
in 318 chronically infected patients.
Materials and Methods
samples
Serum samples were obtained from 318 chronically HCV-
infected patients treated at the Liver Clinic of Seoul
National University Hospital in Korea between March
2002 and July 2003. All of the patients were seropositive
for anti-HCV, as tested by enzyme immunoassay (Abbott
Diagnostics), and positive for serum HCV RNA, as tested
by Cobas Amplicor HCV, Ver. 2.0 (Roche Molecular
Systems). Criteria for exclusion included previous immu-
noglobulin-, interferon-, or other immune- or cytokine-
based therapies with possible activity against HCV. In-
formed consent was obtained from each participant, and
the experimental protocol conformed to the ethics guide-
lines of the 1975 Declaration of Helsinki, as reflected in a
priori approval by the Seoul National University Hospital
Human Research Committee.
HCV RNA extraction and cDNA amplification
HCV RNAs were extracted from 140-L serum samples
by the QIAamp® Viral RNA method (Qiagen) according
to the manufacturer’s instructions. Reverse transcription
and PCR were performed in 1-step reactions. Known
positive and negative sera and water controls were in-
cluded in all reactions from the extraction step. The 5
UTR was amplified with first-round primer pairs de-
scribed previously (23 ): KY80 (sense; 5-GCAGAAAG-
CGTCTAGCCATGGCGT-3; nucleotides 274 to 251)
and KY78 (antisense; 5-CTCGCAAGCACCCTATCAG-
GCAGT-3; nucleotides 29 to 54). For the second
round, we used 2 sets of nested PCR primer. A sense
primer, CV160F, specific to bases 199 to 168 (5-
GTGGTCTGCGGAATCCAACGGTGAGTACACCGGAAT-
3) and an antisense primer, CV100R, specific to bases 67 to
92 (5-TTCGCRACCCAACRCTACTCCAACGGTCCGG-
CTAG-3) were used for detection of sequences from 160 to
100 (R  A or G). A sense primer, CV140F, specific to bases
158 to 140 (5-GACIGGGTCCTGGATGTCTTGGA-3) and
an antisense primer, CV120R, specific to bases 100 to 117
(5-GCGGGGGCACGGATGCCCAAAT-3) were used for
detection of sequences from 140 to 120. As illustrated
in Fig. 1, sequences underlined in the CV160F and
CV100R primers were modified to insert MmeI and
MmeI/AvaII restriction recognition sites, respectively, in
the PCR products, and underlined sequences in the
CV140F and CV120R primers were modified to introduce
FokI sites in the products.
cDNA amplifications were performed with 20-L re-
action mixtures containing 10 L of RNA, 20 mM Tris-
HCl (pH 9.0), 50 mM KCl, 0.2 mM each deoxynucleotide
triphosphate, 1.2 mM MgSO4, 0.4 M each primer, 0.1
mM dithiothreitol, 40 units of RNase inhibitor (Invitro-
gen), 200 U of SuperScriptTM III Moloney murine leuke-
mia virus reverse transcriptase (Invitrogen), and 2.5 U of
Platinum® Taq polymerase (Invitrogen). After incubation
at 50 °C for 45 min and at 94 °C for 2 min, PCR was
performed for 35 cycles; each cycle consisted of denatur-
ation at 94 °C for 15 s, annealing at 55 °C for 15 s, and
extension at 72 °C for 20 s. To 17 L of the second-round
PCR mixture, 1 L of the first-round PCR product was
added. The nested PCR mixture was identical to the
first-round mixture except for the omission of dithiothre-
itol, RNase inhibitor, and Moloney murine leukemia virus
reverse transcriptase. PCR was conducted with the con-
ditions described above, except that the annealing tem-
perature was 60 °C. Nucleotide sequence positions were
numbered according to the prototype HCV type 1 se-
quence (24 ).
RFMP assay for HCV genotyping
Restriction enzyme digestion of the nested PCR product
obtained with the CV160F and CV100R primer pair was
performed by mixing the PCR reaction mixture with 10
L of reaction buffer containing 50 mmol/L potassium
acetate, 20 mmol/L Tris-acetate, 10 mmol/L magnesium
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Fig. 1. Schematic diagram of the RFMP genotyping strategy.
From the alignment of the 5 UTR from published HCV sequences, 3 variable motifs surrounded by conserved regions were chosen: H1, 166 to 150; H2, 101
to 93; and H3, 139 to 118. PCR was performed with primers designed to introduce a type IIS restriction endonuclease recognition sequence (MmeI or FokI) ahead
of the genotype-specific motifs on amplification. Enzymatic cleavage of the products led to excision of multiple oligonucleotide fragments representing the motifs shown
(uppercase sequences); the masses of the resulting oligonucleotide fragments were then examined by MALDI-TOF MS. (A), genotyping strategy for H1 and H2 motifs:
cleavage sites of MmeI (filled arrowheads) and AvaII (open arrowheads); artificially introduced recognition sites of MmeI and a combined MmeI/AvaII (shaded
sequences); and a naturally occurring AvaII site (underlined sequence). (B), genotyping strategy for H3 motif, with cleavage sites of FokI (filled arrowheads) and BstF5I
(open arrowheads), an isoschizomer for FokI, and recognition sites of both restriction endonucleases (shaded sequences).
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acetate, 1 mmol/L dithiothreitol, and 1 U of MmeI (New
England Biolabs). The reaction mixture was incubated at
37 °C for 2 h and then incubated at 37 °C for 2 h with AvaII
(New England Biolabs). Enzyme digestion of the nested
PCR products obtained with the CV140F and CV120R
primer pair was identical, except for the addition of 50
mol/L S-adenosylmethionine in the mixture, the use of
FokI (New England Biolabs), and the subsequent digestion
with BstF5I (New England Biolabs). The resulting digest
was purified by vacuum filtration through a custom-built
384-well sample preparation plate containing 5 mg of
polymeric sorbent per well (Waters) or Oasis® Elution
Plates (Waters). Each well was equilibrated with 90 L of
1 mol/L triethylammonium acetate (TEAA; pH 7.6). Each
cleavage reaction mixture was added to 70 L of 1 mol/L
TEAA (pH 7.6) and loaded in a well. After the wells were
rinsed 5 times with 85 L of 0.1 mol/L TEAA (pH 7.0), the
plate was reassembled on a vacuum manifold and eluted
with 60 L of 600 mL/L isopropanol in water into a
collection plate, which was placed on a heating block at
115 °C for 90 min. The desalted reaction mixtures were
resuspended with matrix solution containing 15 g/L
3-hydroxypicolinic acid, 0.023 mol/L ammonium citrate,
and 120 mL/L acetonitrile; they were then spotted in 3-L
volumes on a polished MTP AnchorChipTM plate (Bruker
Daltonics). Mass spectra were acquired on a Biflex IV
linear MALDI-TOF MS (Bruker Daltonics) workstation
equipped with a 337 nm nitrogen laser and a nominal ion
flight path length of 1.25 m as described previously, with
slight modification (22 ). The samples were analyzed in
negative-ion mode with a total acceleration voltage of 20
kV, extraction voltage of 18.25 kV, laser attenuation of 55,
and delayed extraction of long time delay. Typically,
time-of-flight data from 10 individual laser pulses were
recorded and averaged on a transient digitizer with a time
base of 2 ns and delay of 24 000 ns, after which the
averaged spectra were automatically converted to mass
by the accompanying data-processing software (Bruker
Daltonics). With such settings, the instrument usually
provides mass accuracy of 40–80 ppm (106), mass reso-
lution of 1500–2000, and sensitivity of 10–50 fmol in the 2-
to 6-kDa mass range for oligonucleotides.
validation of RFMP analysis for HCV
genotyping
We compared the RFMP assay results with the results
from both direct sequencing and the clonal sequencing
assay. For confirmation of viral quasispecies or mixed-
genotype infection, we cloned the PCR products into the
PCR-Script Amp cloning vector (Stratagene) for sequence
analysis of each clone (at least 10 clones per sample). The
commercialized genotype controls, Armored RNA®-HCV
genotype 1b and 2a/c (Ambion Diagnostics), were mixed
in various ratios and used to evaluate the sensitivity and
specificity of the RFMP assay. Sequence analysis was
performed by the ABI PRISM 310 Genetic Analyzer (Ap-
plied Biosystems). To clarify the relationship among dif-
ferent HCV isolates, we constructed a phylogenetic tree as
described elsewhere (25 ).
Results
genotyping strategy and theoretical
prediction of database sequences
The RFMP assay is based on mass spectrometric analysis
of small DNA fragments containing genotype-specific
motifs, as illustrated in Fig. 1. The first step requires PCR
amplification using primers flanking the genotype-spe-
cific motifs. From the alignment of the 5 UTR from
published sequences, 3 variable regions, H1 to H3, sur-
rounded by conserved regions were chosen as genotype-
specific motifs of HCV. Two nested sets of universal
primers flanking the variable regions, CV160F/CV100R
and CV140F/CV120R, were selected and modified to
introduce a type IIS restriction endonuclease recognition
sequence ahead of the variable regions on amplification.
For interrogating H1 and H2 motifs, CV160F and CV100R
primers were designed to introduce the MmeI and com-
bined MmeI/AvaII sites in the amplified product by
substituting the restriction recognition sequence TC-
CAAC for CC (nucleotides 186 to 185) and TC-
CAACGGTCC for TC (nucleotides 49 to 50), respec-
tively. To interpret the H3 motif, primers CV140F and
CV120R were designed to introduce a FokI site (an iso-
schizomer of BstF5I) in the amplified product by substi-
tuting the restriction recognition sequence GGATG for T
(nucleotide 147) and G (nucleotide 110), respectively.
When the complementary strands are copied, the inserted
sequences are incorporated into the product. Type IIS
restriction enzymes such as MmeI, FokI, and BstF5I cleave
DNA outside the recognition sequence: MmeI, 20 bases
3 to the recognition site on one strand and 18 bases from
the recognition site on the other strand, leaving a 2-base
overhang protruding 3 end; FokI, 9 bases 3 to the
recognition site on one strand and 13 bases from the
recognition site on the other strand, leaving a 4-base
overhang protruding 5 end; BstF5I, 2 bases 3 to the
recognition site on one strand and immediately 3 to the
recognition site on the opposite strand, leaving a 2-base
overhang. As outlined in Fig. 1, cleavage of a 142-bp
amplified segment with MmeI and AvaII leads to excision
of the 12mer/17mer and 14mer/19mer fragments repre-
senting H1 and H3 motifs, respectively, whereas digestion
of a 67-bp amplified segment with FokI and BstF5I leads to
excision of 2 sets of 7mer/14mer/13mer fragments, re-
flecting the sequence variation of the H2 motif.
HCV 5 UTR sequences retrieved from the Entrez
Nucleotide database of the National Center for Biotech-
nology Information were aligned against the HCV proto-
type 1 sequence (n  871 as of May 2004; queried by “hcv
and 5 UTR”). From some of the reported sequences
covering all 3 variable motifs, we obtained 10 H1, 4 H2,
and 28 H3 mass patterns, and a total of 41 combined
patterns were assigned to the 6 major HCV genotypes
without duplication (see Table 1 of the Data Supplement
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that accompanies the online version of this article at
http://www.clinchem.org/content/vol51/issue7/).
We found 10 different patterns for samples belonging
to type 1, with subtype 1b accounting for the most diverse
mass patterns (6 of 10). Genotype 2 could be divided into
8 patterns, with 138A, 132A, and 128T the most
distinctive bases among this type. The 2a and 2c subtypes
are not completely differentiated, but there is a tendency
that TC at nucleotides 117 to 116 is abundant in
subtype 2a, whereas CC is abundant in subtype 2c. Most
of genotypes 3 and 4 were predicted to show specific
patterns in the H1 motif indicative of the existence of
163G and 159T. The patterns for genotype 4 were
more complicated and diverse, presenting 12 kinds,
among which 4c and 4d could not be differentiated.
Genotypes 5 and 6 showed 2 subtype patterns each. From
these analyses, 6 major genotypes and 27 subtypes of
HCV were predicted to be differentiated into 41 prototype
Fig. 2. Evaluation of the sensitivity of the RFMP assay for detection of minor amounts of virus with a defined mixture of genotypes 1b and 2a/c.
(A), MALDI-TOF MS spectra resulting from mixed populations of genotypes 1b and 2a/c. Only the mass spectra of the 12mer fragments coming from H1 motifs are
shown. Molecular masses of 3761 and 3816 represent 1b- and 2a/c-originated fragments, respectively. Percentages denote [1b/(1b  2a/c)]  100. RI, relative peak
intensity. (B), results of test for linearity between the pooling ratios and the corresponding peak-area ratios across artificial pools with different proportions of genotypes
ranging from 0.5% to 50%. Five replicates of the artificial pool were genotyped to test the repeatability of the method. Error bars, SD. A diagonal line would be expected
for complete concordance between measured and real values (R2  0.992).
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mass patterns as summarized in Table 1 of the online Data
Supplement.
detection of mixed HCV genotypes
To assess the sensitivity and validity of the RFMP assay
for detecting mixed genotypes in a viral population, we
performed the assay with samples composed of defined
ratios of 5 UTR sequences of HCV genotype 1b and 2a/c
in RNAs. The RNAs were mixed in the following propor-
tions of genotype 1b to the mixture of 2a/c and 1b: 50%,
40%, 30%, 20%, 10%, 5%, 0.5%, and 0%. The RFMP assay
detected 0.5% genotype 1b when assessed with 12mer
from the H1 motif (Fig. 2A). The DNA sequencing assay
could not detect genotype 1b mixed with a 5-fold greater
amount of genotype 2a/c, in agreement with previous
reports (26 ).
To test for a relationship between estimated and real
proportions, we calculated ratios using the mean peak
areas generated from multiple mass spectra and com-
pared them with the defined pooling ratios. We observed
a linear correlation of the estimated to the expected
proportions between genotypes in the range from 0.5% to
50% (R2  0.992; Fig. 2B). The significant differences
obtained in dynamic range did not depend on which
spectral band was chosen for quantification among the 10
restriction fragments, except for a pair of 7mers coming
from the H3 motif. The 7mers from the H3 motif showed
a lower limit of minor genotype detection as low as 0.5%
and a dynamic range of 0.5%–50% (R2  0.895). Although
the 7mers from the H3 motif seem inferior to other
fragments in representing the relative abundance of a
mixed-genotype infection, they do not affect the lowest
concentrations needed for distinguishing mixed geno-
types because the sensitivity was comparable to that for
other fragments. The RFMP assay thus could detect mixed
genotypes in a viral population and determine their
relative abundances.
HCV genotype distribution in patients
determined by RFMP analysis
We determined the genotype distribution of the 318
samples from chronically infected patients by RFMP and
its representative spectra (Table 1 and Fig. 1 of the online
Data Supplement). All of the samples were successfully
genotyped by RFMP analysis, and the results agreed with
clonal sequence analysis. Consistent with previous re-
ports, genotypes 1b and 2a/c were the most prevalent,
constituting 83% of the samples (27 ). Of interest, 22% of
the samples were determined to be infected with mixed
genotypes. Similar to single-genotype infections, the 2
predominating genotypes in mixed-genotype infections
were 1b and 2a/c, which were found in 77.3% of the
samples. Of the mixed-genotype infections, 30% were
determined by direct sequencing to be a single genotype
or ambiguous but were further confirmed by clonal
sequencing (data not shown). Among samples with
mixed-genotype infections, genotype 1b was found in
87.1% (61 of 70) of the individuals, and it was commonly
mixed with 2a/c in 42.6% (26 of 61). Of 318 chronic
patients with samples analyzed by the RFMP assay, 21
among 38 cases were observed with deviations that did
not correspond to the predicted mass pattern from the
reference sequences. For example, a motif code pattern
(H1/H2/H3) of 2/2/7 was found in 5 cases diagnosed as
single genotypes, and in 1 case it was mixed with 2/1/7
(genotype 2a/c). Although the sequences lacked an exact
match in Table 1 of the online Data Supplement, they
could be inferred by combining the motif sequences
corresponding to codes 2, 2, and 7 in motif order, as
shown in the first line of genotype 2 in Table 1. The
sequences extracted by the above-mentioned approaches
fully agreed with the sequencing result. By direct com-
parison with or construction of a phylogenetic tree linked
to the known HCV genotype sequences, the 21 types of
mass pattern deviants were assigned to 6 and 15 variants
falling into genotypes 1 and 2, respectively (Table 1).
Discussion
Clinical demand for HCV genotyping is increasing be-
cause of the significance of HCV genotype as a predictor
of treatment response and to enable use of more effica-
cious therapeutic options. Currently, genotyping is per-
formed largely by sequence analysis and hybridization-
based assays (16–18). Sequencing can give information on
the majority species present in the viral populations but
generally fails to detect species comprising less than
15%–50% of a viral population (26 ). It is thus necessary to
analyze multiple clones to determine the genetic hetero-
geneity of a population. Assays based on hybridization
have been widely used as surrogate genotyping methods,
but such assays are labor-intensive, complicate identifica-
tion of genotype variants or genotype mixtures, and are
not suitable for screening large numbers of samples
because of the complex protocols involved.
MS generates precise information on the molecular
mass of the analyte, both DNA strands can be analyzed in
parallel, and the procedure can be fully automated. MS
directly assesses the nature of the PCR products, either as
a whole or as fragmented oligonucleotides, whereas other
technologies only indirectly measure PCR products, ei-
ther through hybridization or by primer-extended
minisequencing reactions, which use PCR products as
templates. Genotyping by creating or abolishing recogni-
tion sites for restriction enzymes, similar to conventional
restriction fragment length polymorphism analysis, has
been used in combination with MALDI MS detection (28 ).
Either naturally occurring restriction sites were used or
base changes were incorporated in one of the PCR prim-
ers to create a recognition site with one of the alleles of the
polymorphic site. Only a small number of polymor-
phisms, however, will alter known restriction sites, and
the design of amplification primers to create restriction
sites in connection with 1 allele is not straightforward in
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most cases, reducing the usefulness of this approach to
very special circumstances.
In this study, we established an RFMP assay for HCV
genotyping that exploits differences among HCV geno-
types in the molecular masses of oligonucleotides com-
prising the viral 5 UTR. The assay is based on amplifica-
tion and mass detection by MALDI-TOF MS of
oligonucleotides excised from type IIS enzyme digestions
(Fig. 1). The use of a type IIS restriction enzyme makes
this assay independent of the chance occurrence of restric-
tion sites because these enzymes have cleavage sites distal
to their recognition sites. Recognition sites are incorpo-
rated into the amplification primers, and short fragments
that contain the polymorphisms can be generated for
mass spectrometric analysis. In addition to its speed and
high-throughput capacity, the RFMP assay is very sensi-
tive. It distinguishes between mixed-genotype infections
when the minor species constitutes as little as 0.5% of the
population (Fig. 2), revealing clear correlations between
peak ratios and relative genotype concentrations in mixed
populations. For samples from 318 chronically infected
patients, the RFMP assay showed excellent concordance
with clonal sequencing and detected diverse polymor-
phisms whose sequences deviated from reported HCV
genotypes (Table 1). The significant incidence of mixed-
genotype infections was detectable because of the assay’s
higher sensitivity, leading us to conclude that HCV
Table 1. Genotype distribution, as determined by RFMP analysis, in single- and mixed-genotype infections in 318 patients
with chronic HCV infections.
Genotype






1a GCCAGGACGACCGGGTC TCAA CCCGCTCAATGCCTGGAG GCAAGACTGCTAGCCG 10 (4) 5 (3.5)
1a/b ----------------- ---- ------------------ -------C-------- 2 (1.4)
1b ----------------- ---- ------------------ --G------------- 102 (41.1) 54 (38.3)
-------T--------- ---- ------------------ --G------------- 4 (1.6) 2 (1.4)
----------------- -T-- ------------------ --G------------- 13 (5.2) 5 (3.5)
1c ----------------- -T-- ------------------ ---------------- 1 (0.4)
1 ----------------- ---- -------T---------- --G------------- 1 (0.4) 2 (1.4)
----------------- ---- -------G---------- --G------------- 1 (0.4)
----------------- ---- -------------C---- --G------------- 1 (0.4)
----------------- -T-- ------------------ -------C-------- 1 (0.4)
----------------- -A-- ------------------ --G------------- 1 (0.4)
----------------- -TC- ------------------ ---------------- 1 (0.4)
2a/c ---G---A---T----- -A-- ---A---T-----C--TC ---------------- 26 (10.5) 19 (13.5)
---G---A---T----- -A-- ---A---T-----C--CC ---------------- 61 (24.6) 29 (20.6)
2b A--G-A-A---T----- -A-- ---A---T---T-C--TC ---------------- 2 (0.8)
2d -------A---T----- -A-- ---A---T--------TC ---------------- 1 (0.4) 5 (3.5)
2e ---G---A---T----- -A-- ---A---T-----C--TC -------C-------- 1 (0.4) 7 (5.0)
2 ---G---A---T----- -A-- ---A---T-----C--CC -------C-------- 5 (2.0) 1 (0.7)
---G---A---T----- -A-- ---A---TG----C--CC -------C-------- 1 (0.4)
---G---A---T----- A--- ---A---TG----C--CC ---------------- 1 (0.4) 4 (2.8)
---G---A---T----- G---A---A---T-----C--CC ---------------- 1 (0.4)
---G---A---T----- A--- ---A---T-----C--CC ---------------- 1 (0.4) 1 (0.7)
-------A---T----- -A-- ---A---T-----C--CC -------C-------- 1 (0.4) 1 (0.7)
---G---A---T----- -A-- ---A---T-----C--TC --G------------- 1 (0.4)
--TG---G---T----- -A-- ---A---C-----C--CC ---------------- 1 (0.4)
-------A---T----- -A-- ---A---T--------TC -------C-------- 1 (0.4) 1 (0.7)
-------A---T----- -A-- ---A---T--------CC -------C-------- 1 (0.4) 2 (1.4)
---G---A---T----- CA-- ---A---C-----C--CC ---------------- 1 (0.4)
---G---A---T----- -A-- ---A---T--------CC ---------------- 1 (0.4) 1 (0.7)
---G---A---T----- -A-C ---A---C-----C--CC ---------------- 1 (0.4)
---G---A---T----- -G-- ---A---T-----C--CC ---------------- 1 (0.4)
A--G-A-A---T----- -AC- ---A---T---T-C--TC -------C-------- 1 (0.4)
3e --TG--GT--------- A--- ----------A--CA--A --G---TCA------- 2 (0.8)




a The 1-base insertion between 136 and 135 in the H3 motif is blanked for easy comparison.
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mixed-genotype infections are more common than previ-
ously estimated.
Taken together with previous findings that mixed
infections seem to be associated with unfavorable disease
outcomes and that detection of minor genotypes before
antiviral therapy may be important for choosing an ade-
quate regimen (21, 29–31), our results indicate that fur-
ther testing of mixed-genotype infections is needed to
expand current treatment algorithms that rely on specific,
single genotypes. This research should be facilitated by
the high sensitivity of the RFMP assay for detecting mixed
infections and the capacity of the RFMP assay to deter-
mine relative abundances among viral species. In terms of
cost-effectiveness, we estimated the direct cost per test
(reagents and labor) of the RFMP assay to be $30.00
(US), including viral nucleic acid extraction, PCR, restric-
tion digestion, restriction fragment purification, and ma-
trix, which is much less expensive than the line probe
assay at $130.00 (US) per test. Assuming that the capital
equipment costs for the Biflex IV in our laboratory,
estimated at $50 000.00 including annual amortization
and maintenance, are similarly applicable, clinical labora-
tories that expect to test 500 specimens referred for HCV
genotyping per year could consider the RFMP assay as an
alternative to the line probe assay. In laboratories already
using MALDI-TOF MS for clinical genotyping or for
clinical proteomics, these costs could be avoided or min-
imized because the same instrumentation is used for the
RFMP assay.
Accurate determination of ion masses is achievable
because of high mass resolution and low ppm precision in
the peak centroid positions for the raw flight time data
(32, 33), which are necessary features for resolving adja-
cent peaks, particularly with increasing oligonucleotide
fragment size. Although the absolute error, on average,
was less than 0.5 Da and the width of the mass peak at
the half maximum was as low as 1–4 Da for 2- to 6-kDa
mass ranges in our experimental setup, concerns could
arise relating to distinctions between multiple fragments
of extremely similar masses, such as codes 1 and 4 of
motif H2, and consequently between genotypes 1a (codes
1/1/1) and 1b (1/4/1) if present in the same specimen.
The resolution achieved by the RFMP assays reported
here should be achievable with MALDI-TOF MS instru-
ments with specifications and settings comparable to or
beyond those used here. A limitation of the RFMP assay,
however, is that it determines only molecular mass and,
therefore, will fail to detect alterations in sequences that
do not lead to a change in molecular mass. To provide
certainty in such cases, anticipated from the reported
sequences as exemplified in Table 1 of the online Data
Supplement for codes 3 and 6 of motif H1 and code 1 of
motif H2, we designed the assay so that mass patterns
obtained from other motifs would enable exact genotype
differentiation. The presence of a novel genotype variant
with sequence alterations that do not cause a deviation
from the molecular mass pattern predicted from up-to-
date HCV databases is possible, but we believe it would
be extremely rare, as corroborated by the fact that we
found no such case in 318 patients by either RFMP or
sequencing assays. Alternative mass spectrometric tech-
niques to consider involve collision-induced dissociation
of polyprotonated oligonucleotides produced by electro-
spray ionization introduced to allow de novo sequencing
of DNA oligomers up to 19 bases in length (34 ). Even
longer fragments could be handled if the sequences differ
at not more than 2 nucleotide positions from a reference
sequence with mass-to-charge values predicted by estab-
lished fragmentation pathways (35 ). These techniques
could be considered to investigate potential sequence
variations leading to no change in molecular mass, al-
though whether they are amenable to high-throughput
genotyping of multiple variations for clinical applications
is not yet established.
In conclusion, the RFMP genotyping method uses the
mass difference of oligonucleotides, requires the simple
steps of single PCR amplification and restriction enzyme
digestion, and is amenable to high-throughput analyses.
The RFMP method has practical advantages over existing
methods, including more sensitive and specific detection
of mixed populations, as well as primary screening of
novel viral genotype variants leading to deviation from
the predicted reference mass patterns without need for
cloning or multiple PCR steps. This screening method
allows reliable viral genotyping in laboratories and effi-
cient analysis of large samples and viral quasispecies to
address the dynamics of HCV infections and the relation-
ship between HCV genotypes and clinical outcome. The
RFMP genotyping assay is easily adaptable for the detec-
tion of other genetic variations, including polymor-
phisms, deletions, and additions, as well as motifs with
multiple variations, because the range and sizes of the
resulting restriction fragments analyzed in MALDI-TOF
MS can be chosen according to the investigator’s needs.
We believe, therefore, that the RMFP genotyping assay
will be quite useful for developing molecular diagnostics
needed to differentiate clusters of multiple variations,
such as virus genotyping, and for conducting pharmacog-
enomic studies of multiple single-nucleotide polymor-
phisms.
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